0.533
price down icon3.07%   -0.0169
after-market Handel nachbörslich: .54 0.007 +1.31%
loading

Curis Inc Aktie (CRIS) Neueste Nachrichten

pulisher
Apr 04, 2026

CRIS Should I Buy - Intellectia AI

Apr 04, 2026
pulisher
Apr 03, 2026

Curis Inc. (CUS0.SG) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada

Apr 03, 2026
pulisher
Apr 02, 2026

Curis, Inc. (CRIS) stock price, news, quote and history - Yahoo Finance Singapore

Apr 02, 2026
pulisher
Apr 02, 2026

CRIS Stock Price, Quote & Chart | CURIS INC (NASDAQ:CRIS) - ChartMill

Apr 02, 2026
pulisher
Apr 01, 2026

Curis director Kaitin buys $5487 in shares By Investing.com - Investing.com South Africa

Apr 01, 2026
pulisher
Apr 01, 2026

Curis director Kaitin buys $5487 in shares - Investing.com UK

Apr 01, 2026
pulisher
Apr 01, 2026

Director at Curis (NASDAQ: CRIS) makes open-market share buy - Stock Titan

Apr 01, 2026
pulisher
Mar 31, 2026

Curis targets full enrollment in PCNSL registrational study within 12–18 months while advancing CLL proof-of-concept - MSN

Mar 31, 2026
pulisher
Mar 30, 2026

Market Review: What are analysts price targets for Curis IncQuarterly Risk Review & Fast Exit and Entry Trade Guides - baoquankhu1.vn

Mar 30, 2026
pulisher
Mar 30, 2026

Curis prices private placement of $80.8M - MSN

Mar 30, 2026
pulisher
Mar 28, 2026

Aug Big Picture: Is Curis Inc exposed to political riskMarket Sentiment Summary & Weekly Top Gainers Alerts - baoquankhu1.vn

Mar 28, 2026
pulisher
Mar 27, 2026

Stonepine Group (NASDAQ: CRIS) reports 4.03M shares, 9.9% stake - Stock Titan

Mar 27, 2026
pulisher
Mar 24, 2026

Curis, Inc. 2025 Annual Report: Emavusertib Development, Regulatory Pathways, and Key Business Risks - Minichart

Mar 24, 2026
pulisher
Mar 24, 2026

Curis (NASDAQ: CRIS) warns on going concern amid emavusertib push - Stock Titan

Mar 24, 2026
pulisher
Mar 23, 2026

CURIS (CRIS) CDO Jonathan Zung converts Series B preferred into 66,667 common shares - Stock Titan

Mar 23, 2026
pulisher
Mar 23, 2026

Curis (CRIS) CMO converts Series B preferred stock to common shares - Stock Titan

Mar 23, 2026
pulisher
Mar 23, 2026

CURIS INC (CRIS) CFO converts Series B preferred into 66,666 common shares - Stock Titan

Mar 23, 2026
pulisher
Mar 23, 2026

Curis (CRIS) CEO converts Series B preferred stock into common shares - Stock Titan

Mar 23, 2026
pulisher
Mar 23, 2026

Curis Inc (CRIS) director converts Series B preferred into 26,667 common shares - Stock Titan

Mar 23, 2026
pulisher
Mar 23, 2026

Curis, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 23, 2026
pulisher
Mar 23, 2026

[EFFECT] CURIS INC SEC Filing - Stock Titan

Mar 23, 2026
pulisher
Mar 20, 2026

Curis Earnings Call: Clinical Momentum Amid Revenue Void - TipRanks

Mar 20, 2026
pulisher
Mar 20, 2026

Curis (CRIS) EPS Soars 210.8% to $1.23, But Revenue Plunges 67.1% to $1.1M - AlphaStreet

Mar 20, 2026
pulisher
Mar 20, 2026

Curis (CRIS) Q4 2025 Earnings Call Transcript - AOL.com

Mar 20, 2026
pulisher
Mar 20, 2026

Curis Inc stock faces renewed scrutiny amid pipeline delays and cash burn concerns - AD HOC NEWS

Mar 20, 2026
pulisher
Mar 20, 2026

Curis, Inc. (NASDAQ:CRIS) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 20, 2026
pulisher
Mar 20, 2026

CRIS: HC Wainwright & Co. Reiterates Buy Rating with $17.00 Pric - GuruFocus

Mar 20, 2026
pulisher
Mar 20, 2026

Curis reports Q4 results, secures up to $80.8M financing By Investing.com - Investing.com India

Mar 20, 2026
pulisher
Mar 20, 2026

Curis Inc (CRIS) Q4 2025 Earnings Call Highlights: A Turnaround with Strong Quarterly Profit ... By GuruFocus - Investing.com Canada

Mar 20, 2026
pulisher
Mar 19, 2026

Curis Inc (CRIS) Q4 2025 Earnings Call Highlights: A Turnaround with Strong Quarterly Profit and Strategic Focus - gurufocus.com

Mar 19, 2026
pulisher
Mar 19, 2026

Curis Q4 2025 Earnings Call Transcript - MarketBeat

Mar 19, 2026
pulisher
Mar 19, 2026

Curis, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Mar 19, 2026
pulisher
Mar 19, 2026

Earnings call transcript: Curis Inc. Q4 2025 sees turnaround with net income - Investing.com India

Mar 19, 2026
pulisher
Mar 19, 2026

Curis Inc’s NHL Prioritization, PCNSL Timeline Shifts, and CLL Data Delays Clash in 2025 Q4 Earnings Call - Bitget

Mar 19, 2026
pulisher
Mar 19, 2026

Curis Reports Progress on Lymphoma Study & Expands CLL Research with EmavusertibNews and Statistics - IndexBox

Mar 19, 2026
pulisher
Mar 19, 2026

Curis (CRIS) Q4 2025 Financial Results Conference Call Transcript - Bitget

Mar 19, 2026
pulisher
Mar 19, 2026

Earnings call transcript: Curis Inc. Q4 2025 sees turnaround with net income By Investing.com - Investing.com South Africa

Mar 19, 2026
pulisher
Mar 19, 2026

Curis Provides Fourth Quarter 2025 Business Update - GuruFocus

Mar 19, 2026
pulisher
Mar 19, 2026

Curis: Fourth Quarter Earnings Overview - Bitget

Mar 19, 2026
pulisher
Mar 19, 2026

Curis Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 19, 2026
pulisher
Mar 19, 2026

Curis (CRIS) Q4 2025 Earnings Call Transcript - The Motley Fool

Mar 19, 2026
pulisher
Mar 19, 2026

Curis (CRIS) Reports Lower Than Expected Q4 Revenue - gurufocus.com

Mar 19, 2026
pulisher
Mar 19, 2026

Curis Q4 & Full-Year 2025 Financial Results: $19.4M Net Income, $1.1M RevenueNews and Statistics - IndexBox

Mar 19, 2026
pulisher
Mar 19, 2026

Curis: Overview of Fourth Quarter Financial Results - Bitget

Mar 19, 2026
pulisher
Mar 19, 2026

Curis reports Q4 results, secures up to $80.8M financing - Investing.com

Mar 19, 2026
pulisher
Mar 19, 2026

Curis Inc Q4 revenue misses estimates - TradingView

Mar 19, 2026
pulisher
Mar 19, 2026

Curis: Q4 Earnings Snapshot - marketscreener.com

Mar 19, 2026
pulisher
Mar 19, 2026

Curis (CRIS) swings to Q4 profit but warns of funding shortfall - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

Curis’s Emavusertib Trial Pause: What AML and MDS Investors Need to Know - TipRanks

Mar 19, 2026
$48.77
price down icon 0.87%
$27.88
price down icon 1.59%
$47.32
price down icon 2.57%
$91.28
price up icon 0.11%
ONC ONC
$302.49
price down icon 2.67%
$163.81
price up icon 0.85%
Kapitalisierung:     |  Volumen (24h):